MARKET NEWS

Organicell Provides Phase 1/2 Clinical Trial Update
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement With UNION Therapeutics
Mustang Bio Announces Rare Pediatric Disease Designation
CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data & Initiation of Blinded, Placebo-Controlled Trial
G1 Therapeutics Announces Acceptance & Priority Review of NDA 
Avacta & LG Chem Life Sciences Expand Partnership

  FEATURED EDITORIAL

  COMPANY PROFILE

ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions, for pharmaceutical and biopharmaceutical, flood protection, personal protection, bulk packaging, and aerospace industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions since 1947. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ANA Therapeutics & Quotient Sciences Announce Manufacturing Partnership

ANA Therapeutics & Quotient Sciences Announce Manufacturing Partnership

ANA Therapeutics, a Silicon Valley-based biotech start-up, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, recently announced a partnership to support the….

EyePoint Pharmaceuticals Receives .5 Million From Ocumension Therapeutics Under Expanded License Agreements

EyePoint Pharmaceuticals Receives $9.5 Million From Ocumension Therapeutics Under Expanded License Agreements

EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics recently announced the expansion of their exclusive license agreements for the development and commercialization of….

Humanetics Corporation & Pharmaceutics International, Inc. Announce Partnership 

Humanetics Corporation & Pharmaceutics International, Inc. Announce Partnership 

Humanetics Corporation and Pharmaceutics International, Inc. (Pii) will work together to support a clinical trial of BIO 300 in COVID-19 patients…..

Ingenza Meets a key Milestone in the Deployment of Novel Cost-Effective COVID-19 Vaccine Technology

Ingenza Meets a key Milestone in the Deployment of Novel Cost-Effective COVID-19 Vaccine Technology

Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 2 – Drug Delivery
September 9 – Injection Devices